+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cell Surface Markers - Global Market Trajectory & Analytics

  • ID: 3502817
  • Report
  • January 2021
  • Region: Global
  • 499 Pages
  • Global Industry Analysts, Inc
Demand for Cancer Screening Builds Up, Following Months of Delayed Care. Cell Surface Markers to Reach $1.1Billion

Global market for Cell Surface Markers is expected to reach US$ 1.1 billion by the year 2027 trailing a post pandemic growth rate of 8.9% for the period 2020 to 2027.Several health systems across the world have begun resuming non-COVID-19 care procedures. Demand is expected to spike in the coming months as delayed care leads to management of more critical cases. The impact of delayed care in oncology is especially expected to be severe with delayed diagnosis and lack of timely treatment likely to increase healthcare costs and mortality. The scenario is expected to create pent-up demand for cancer screening worldwide and spur demand for cell surface markers for cancer stem cells used in diagnostics & drug delivery. Both the United States and the U.K have witnessed over 65% reduction in breast cancer checks during Covid-19. Hospitals the world over will be faced with a huge backlog of cancer screening tests which has been accumulating during the Covid-19 pandemic to be cleared in the coming months. The scenario is a significant setback to the global fight against cancer. Missed diagnosis and delayed surgeries are expected to push up cancer mortality rates significantly over the next few years.

Cell surface markers or cell surface antigens are special carbohydrates or proteins present on cell membrane and can be exploited for identification and classification of cells. While certain proteins participate in transportation of molecules through the membrane, cell surface markers hold a pivotal role in intercellular recognition and communication. These surface markers act exclusive fingerprint of a cell and can be used in a diverse spectrum of applications. Cell surface markers are finding increasing use in research, disease diagnosis, drug discovery, personalized medicine and direct treatment for a specific medical condition. These markers allow researchers to determine cell expression of specific receptors to gain insights into biological response. Cell surface markers are commonly used to evaluate cell proliferation and abnormal cell population along with assessment and quantification of residual diseases. The increasing focus on timely diagnosis for disease prevention and reducing burden on healthcare system is driving the demand for cell surface markers. Over the years, application of cell surface markers has expanded beyond lymphocytes to detection of monocytes, macrophages, progenitor cells, and tumor cells. Cell surface markers exhibit the potential to revolutionize stem cell research. Other exciting areas include personalized medicine wherein analysis and understanding of cells isolated from patients and their response to specific therapy would allow the physician to make safer and effective medical decisions. Further, the introduction of monoclonal antibody producing hybridoma technology is further expanding the application options for cell surface markers. A growing number of healthcare facilities including hospitals, doctor`s offices, and diagnostic centers, as well as research entities including pharmaceutical laboratories, independent research institutions, academic/university research programs, and contract research organizations are prioritizing cell surface markers identification in diagnosis as well as research applications.

An interesting new application area is the growing focus of the researcher community to identify cell surface markers associated with COVID-19 to aid in diagnosis. Researchers have noted variations in immunological state, particularly changes in the normal ratio between CD4 and CD8 ratio in viral infections owing to antiviral immune responses. The normal CD4:CD8 ratio, 2:1, is inverted to less than 1:1 in certain viral infections, which can be used as diagnostic marker. In a recent effort in this direction, researchers used flow cytometry to determine the number of CD4 T and CD8 T cells in blood specimens of COVID-19 patients for finding the CD4:CD8 ratio. Researchers also determined the mean fluorescence intensity (MFI) of cellular markers for identifying their expression. The close resemblance of symptoms of common cold with initial signs of COVID-19 is prompting various hospitals to consider C-reactive protein (CRP) reagents to differentiate the two conditions. CRP is a primary cell marker that can assist physicians in diagnosing and follow-up treatment for the novel coronavirus (2019-nCoV). Patients with fever and a number of other suspected symptoms undergo CRP along with whole blood cell count testing to help clinicians in identifying common cold from COVID-19 infection. Physicians also conduct nucleic acid test and chest imaging to confirm patients with COVID-19. In addition, clinicians monitor CRP and other biochemical markers during the treatment through to patient recovery.

Select Competitors (Total 70 Featured):

  • Abbott Laboratories, Inc.
  • BD Biosciences
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols, S.A.
  • Immucor, Inc.
  • Nihon Kohden Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Frequently Asked Questions about the Global Market for Cell Surface Markers

What is the estimated value of the Global Market for Cell Surface Markers?

The Global Market for Cell Surface Markers was estimated to be valued at $574.9 Million in 2020.

What is the growth rate of the Global Market for Cell Surface Markers?

The growth rate of the Global Market for Cell Surface Markers is 6.9%, with an estimated value of $916.1 Million by 2027.

What is the forecasted size of the Global Market for Cell Surface Markers?

The Global Market for Cell Surface Markers is estimated to be worth $916.1 Million by 2027.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Cell Surface Markers: A Prelude
  • Researchers Identify Over-Expression of CD8 Marker on Cytotoxic T-Cells in Patients with COVID-19 Infection
  • Hospitals Eye on CRP as Diagnostic Marker to Distinguish Common Cold from COVID-19
  • Robust Demand for Analytical Techniques and Focus on Timely Diagnosis Drive Growth of Global Cell Surface Markers Market
  • Research Dominates Cell Surface Markers Market, Clinical Diagnostics to Exhibit Fastest Growth
  • Flow Cytometers Lead the Cell Surface Markers Market
  • T and B Cells Dominate the Market
  • Developed Regions: Major Revenue Contributors
  • Developing Regions Drive Future Growth

2. FOCUS ON SELECT PLAYERS
  • Recent Market Activity
  • Innovations & Advancements

3. MARKET TRENDS & DRIVERS
  • High Uptake in Drug Discovery Applications Widens Market Prospects
  • Role of Flow Cytometry in Cell Line Development
  • Multicolor Flow Cytometry Offers Perfect Option to Understand B-Cell Development
  • Hematology Analyzers Gain Traction in Cell Surface Marker Identification
  • Growing Hematology Analyzers Market Witnesses Steady Growth
  • Key Technology Trends in Hematology Analyzers Market
  • Rising Cancer Incidence Worldwide Spurs Demand For Cell Surface Markers
  • Select Markers for Cancer Stem Cell Identification
  • EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • EXHIBIT 2: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
  • EXHIBIT 3: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • Use of CD Markers in Identification and Classification of Leukocyte Populations
  • Most Common CD markers for Flow Cytometry
  • Growing Significance of Personalized Medicine: An Opportunity for Cell Surface Markers
  • EXHIBIT 4: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019 and 2024
  • RNA Sequencing Emerges as Potential Approach to Identify Cell Surface Markers for Enabling Precision Medicine
  • Cell Surface Markers Grow Significantly in Stem Cell Research
  • Select Cell Surface Markers Used in Stem Cell Identification and Characterization
  • Hematopoietic Stem Cell Markers Provide Useful Insights into Hematopoiesis
  • Genetically Engineered CAR T-Cells Present Potential Weapon to Eliminate Cancer Stem Cells and Prevent Recurrence of Cancer
  • Key Models
  • CSC Population & Noteworthy Markers
  • ALDH
  • CD44
  • CD90
  • CD133
  • EpCAM & EGFR
  • Immunotherapy Targets Natural Killer Cells to Offer Hope for Cancer Patients
  • Cell Surface Markers Identification Assumes Critical Importance amid Growing Prevalence of Chronic Diseases
  • EXHIBIT 5: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • EXHIBIT 6: Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Aging Demographics Present Opportunities for Cell Surface Markers
  • EXHIBIT 7: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Clinical Management of Autoimmune Diseases
  • Flow Cytometry Remains the Gold Standard in HIV Testing and Monitoring
  • EXHIBIT 8: Global HIV Prevalence: 2019
  • Increased Emphasis on Lab Automation Builds Opportunities
  • Increasing Investments on Advanced Equipment in Disease Diagnosis Underpin Volume Growth
  • Growing Focus on Data Management in Research Programs Extends Opportunities
  • Rat Markers
  • Lineage and Antibodies Specific Rat Markers
  • Commonly Used Key Rat Markers by Antibodies and Research Area/Target Cell
  • New Anti-Rat Antibodies Products Expand Scope of Applications
  • ED Clone Anti-Rat Antibodies by Marker and Cell Type
  • Rat Flow Cytometry Panels

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS
  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
  • Largest Market for Cell Surface Markers
  • Rising Cancer Cases Spur Growth in Cell Surface Markers Market
  • EXHIBIT 9: Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • EXHIBIT 10: Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • Market Benefits from Growing Funding for Stem Cell Research
  • EXHIBIT 11: Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017
  • Market Analytics
  • CANADA
  • High Focus on Improving Healthcare Augurs Well for Market Growth
  • EXHIBIT 12: Number of New Cancer Cases in Canada: 2019
  • Market Analytics
  • JAPAN
  • CHINA
  • Increasing Cancer Research to Drive Cell Surface Markers Market
  • EXHIBIT 13: Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
  • Market Analytics
  • EUROPE
  • Market Facts & Figures
  • EXHIBIT 14: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • Market Analytics
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Increased Cancer Research to Drive the Market for Cell Surface Markers
  • EXHIBIT 15: Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
  • Market Analytics
  • AUSTRALIA
  • INDIA
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA

IV. COMPETITION
  • Total Companies Profiled: 187
Note: Product cover images may vary from those shown